Marek is a partner in the Corporate Practice and currently serves as one of the firm’s Joint Managing Partners. He advises companies and investors who are active in IP-rich sectors; in particular the life sciences, technology and consumer products sectors.
Marek has a broad transactional practice that includes debt and equity financings, M&A, spin-outs, joint ventures, restructurings and complex commercial agreements.
Marek’s clients include several of the world’s largest biopharmaceutical and technology companies, as well as fast-growing companies and specialist investors.
- BA History & Anthropology, University College London
- Qualified 2003
- Partner 2010
- Joint Managing Partner 2016
What others say
"Marek Petecki is knowledgeable about finance, commercial contracts and M&A, and is a well-known name among global bio-pharma and technology companies."Legal 500 2021
"The ‘highly responsive, commercial’ Marek Petecki is a ‘standout partner’ who ‘finds and communicates practicable solutions to issues, and tailors his work carefully’; he is noted for his strength in M&A involving IP and technology. Petecki’s highlights included advising AstraZeneca on the £135m sale of its pharmaceutical manufacturing facility in Avonmouth to Avara."Legal 500 2017
"Marek Petecki advised Diageo on a joint venture with entrepreneur Piers Adam to develop a new whisky brand, Copper Dog, among other matters."Legal 500 2017
"The ‘knowledgeable, calm, pragmatic and extremely responsive’ Marek Petecki advised AstraZeneca UK on the $215m sale of its rights in prescription medicine, Entocort, to Tillots."Legal 500 2016
"Marek Petecki...key figure in the team, who acts for clients including Blooms Properties and Pearl Diver Capital."Legal 500 2016
"Marek Petecki is a key contact"Chambers and Partners 2015
M&A: smaller deals up to £50m
Legal 500 2021
Life Sciences and Healthcare
Legal 500 2021
Legal 500 2017